Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551

T. MinDiabetes Research Group, School of Medicine, Swansea University, Swansea, Wales, UK;Department of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

L. WaliDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

D.M. WilliamsDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

E. PlummerDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

A. GurungDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

J.W. StephensDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK;Diabetes Research Group, School of Medicine, Grove Building, Swansea University, Swansea SA6 8NL, Wales, UKCorrespondence[email protected]

"Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551." Current Medical Research and Opinion, 33(9), pp. 1715–1716

Transparency

Declaration of funding

This letter was not funded.

Declaration of financial/other relationships

J.W.S. has disclosed that he has received a research grant from AstraZeneca. T.M., L.W., D.M.W., E.P. and A.G. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

Acknowledgments

We acknowledge the help of Dr David Price (Morriston Hospital) for his assistance with database management.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551

Declaration of funding

Declaration of financial/other relationships

Information for

Open access

Opportunities

Help and information

Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551

Transparency

Declaration of funding

Declaration of financial/other relationships

Acknowledgments

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature